Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|93|4|299-301

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.93, Iss.4, 2013-04, pp. : 299-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 12, 2015-12 ,pp. : 1427-1437

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Map of Alzheimer's Disease–Signaling Pathways: A Hope for Drug Target Discovery

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 5, 2013-05 ,pp. : 399-401

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systems biology‐embedded target validation: improving efficacy in drug discovery

By  

WILEY INTERDISCIPLINARY REVIEWS: SYSTEMS BIOLOGY AND MEDICINE (ELECTRONIC), Vol. 6, Iss. 1, 2014-01 ,pp. : 1-11

John Wiley & Sons Inc

Access to resources Recommend Favorite

Network‐Based Approaches in Drug Discovery and Early Development

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 651-658

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systems‐Based Discovery Advances Drug Development

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 285-287

John Wiley & Sons Inc

Access to resources Recommend Favorite